|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2002
Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice
1 Worldwide Epidemiology and 2 Statistics and Programming Depts, GlaxoSmithKline Research and Development, Greenford, and 3 Clinical Respiratory Dept, GlaxoSmithKline Research and Development, Stockley Park, UK. 4 Respiratory and Environmental Health Research Unit, Municipal Institute of Medical Research, Barcelona, Spain. 5 Dept of Respiratory Medicine, Hvidovre University Hospital, Copenhagen, Denmark. 6 Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, UK
CORRESPONDENCE: J.B. Soriano, Worldwide Epidemiology, GlaxoSmithKline R&D, Greenford Road, Greenford, Middlesex, UB6 0HE, UK. Fax: 44 20 89662475. E-mail: joan.b.soriano@gsk.com
Keywords: chronic obstructive pulmonary disease, epidemiology, fluticasone propionate, General Practice Research Database, salmeterol, survival
Received: December 5, 2001
Accepted May 7, 2002
Despite substantial evidence regarding the benefits of combined use of inhaled corticosteroids and long-acting ß2-agonists in asthma, such evidence remains limited for chronic obstructive pulmonary disease (COPD). Observational data may provide an insight into the expected survival in clinical trials of fluticasone propionate (FP) and salmeterol in COPD.
Newly physician-diagnosed COPD patients identified in primary care during 1990–1999 aged
Survival at year 3 was significantly greater in FP and/or salmeterol users (78.6%) than in the reference group (63.6%). After adjusting for confounders, the survival advantage observed was highest in combined users of FP and salmeterol (hazard ratio (HR) 0.48 (95% confidence interval 0.31–0.73)), followed by users of FP alone (HR 0.62 (0.45–0.85)) and regular users of salmeterol alone (HR 0.79 (0.58–1.07)) versus the reference group. Mortality decreased with increasing number of prescriptions of FP and/or salmeterol.
In conclusion, regular use of fluticasone propionate alone or in combination with salmeterol is associated with increased survival of chronic obstructive pulmonary disease patients managed in primary care.
50 yrs, of both sexes and with regular prescriptions of respiratory drugs were identified in the UK General Practice Research Database. Three-year survival in 1,045 COPD patients treated with FP and salmeterol was compared with that in 3,620 COPD patients who regularly used other bronchodilators but not inhaled corticosteroids or long-acting ß2-agonists. Standard methods of survival analysis were used, including adjustment for possible confounders.
This article has been cited by other articles:
|
|
 |
|
  S. Suissa and P. J. Barnes Inhaled corticosteroids in COPD: the case against Eur. Respir. J., July 1, 2009; 34(1): 13 - 16. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa Statistical methods in pharmacoepidemiology: advances and challenges Statistical Methods in Medical Research, February 1, 2009; 18(1): 3 - 6. [PDF]
|
|
|
|
 |
|
 B. R. Celli Update on the Management of COPD Chest, June 1, 2008; 133(6): 1451 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Falk, O. A. Minai, and Z. Mosenifar Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 506 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Sridhar, R Taylor, S Dawson, N J Roberts, and M R Partridge A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease Thorax, March 1, 2008; 63(3): 194 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa Immortal Time Bias in Pharmacoepidemiology Am. J. Epidemiol., February 15, 2008; 167(4): 492 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Suissa, R. McGhan, D. Niewoehner, and B. Make Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 535 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Roche Where current pharmacological therapies fall short in COPD: symptom control is not enough Eur. Respir. Rev., September 1, 2007; 16(105): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M.A. Calverley, J. A. Anderson, B. Celli, G. T. Ferguson, C. Jenkins, P. W. Jones, J. C. Yates, J. Vestbo, and the TORCH investigators Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease N. Engl. J. Med., February 22, 2007; 356(8): 775 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Macie, K. Wooldrage, J. Manfreda, and N. R. Anthonisen Inhaled Corticosteroids and Mortality in COPD. Chest, September 1, 2006; 130(3): 640 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Sin and S. F. P. Man Pharmacotherapy for Mortality Reduction in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, September 1, 2006; 3(7): 624 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Scott, P Walker, and P M A Calverley COPD exacerbations {middle dot} 4: Prevention Thorax, May 1, 2006; 61(5): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Marti, X. Munoz, J. Rios, F. Morell, and J. Ferrer Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur. Respir. J., April 1, 2006; 27(4): 689 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Celli Chronic Obstructive Pulmonary Disease: From Unjustified Nihilism to Evidence-based Optimism. Proceedings of the ATS, January 1, 2006; 3(1): 58 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Donohue Combination Therapy for Chronic Obstructive Pulmonary Disease: Clinical Aspects Proceedings of the ATS, November 1, 2005; 2(4): 272 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Johnson Corticosteroids: Potential {beta}2-Agonist and Anticholinergic Interactions in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 320 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J J Soler-Cataluna, M A Martinez-Garcia, P Roman Sanchez, E Salcedo, M Navarro, and R Ochando Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax, November 1, 2005; 60(11): 925 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Petty Are COPD and Lung Cancer Two Manifestations of the Same Disease? Chest, October 1, 2005; 128(4): 1895 - 1897. [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Kiri, N. B. Pride, J. B. Soriano, and J. Vestbo Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Results from Two Observational Designs Free of Immortal Time Bias Am. J. Respir. Crit. Care Med., August 15, 2005; 172(4): 460 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gunen, S. S. Hacievliyagil, F. Kosar, L. C. Mutlu, G. Gulbas, E. Pehlivan, I. Sahin, and O. Kizkin Factors affecting survival of hospitalised patients with COPD Eur. Respir. J., August 1, 2005; 26(2): 234 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Buhl and S. G. Farmer Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004 Thorax, April 1, 2005; 60(4): 343 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C E Brightling, S McKenna, B Hargadon, S Birring, R Green, R Siva, M Berry, D Parker, W Monteiro, I D Pavord, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease Thorax, March 1, 2005; 60(3): 193 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. A. Calverley Effect of Corticosteroids on Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 161 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The TORCH Study Group The TORCH (TOwards a Revolution in COPD Health) survival study protocol Eur. Respir. J., August 1, 2004; 24(2): 206 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. El-Kassimi and N. A. Hanania Differentiating Asthma and COPD Patients Chest, August 1, 2004; 126(2): 653 - 655. [Full Text] [PDF]
|
|
|
|
|
|
D. W. Mapel Treatment Implications on Morbidity and Mortality in COPD Chest, August 1, 2004; 126(2_suppl_1): 150S - 158S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Suissa From the Author Eur. Respir. J., July 1, 2004; 24(1): 191 - 192. [Full Text] [PDF]
|
|
|
|
|
|
V.A. Kiri, J. Vestbo, N.B. Pride, and J.B. Soriano Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur. Respir. J., July 1, 2004; 24(1): 190 - 191. [Full Text] [PDF]
|
|
|
|
 |
|
 T J Ringbaekl, K Viskuml, and P Lange BMI and oral glucocorticoids as predictors of prognosis in COPD patients on long-term oxygen therapy Chronic Respiratory Disease, April 1, 2004; 1(2): 71 - 78. [Abstract] [PDF]
|
|
|
|
|
|
P. M. A. Calverley Reducing the Frequency and Severity of Exacerbations of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2004; 1(2): 121 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Suissa Inhaled steroids and mortality in COPD: bias from unaccounted immortal time Eur. Respir. J., March 1, 2004; 23(3): 391 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Punnam In-Hospital Mortality and Long-term Use of Inhaled Corticosteroids Arch Intern Med, January 26, 2004; 164(2): 222 - 222. [Full Text] [PDF]
|
|
|
|
|
|
V. S. Fan, C. L. Bryson, J. R. Curtis, S. D. Fihn, P.-O. Bridevaux, M. B. McDonell, and D. H. Au Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease and Risk of Death and Hospitalization: Time-dependent Analysis Am. J. Respir. Crit. Care Med., December 15, 2003; 168(12): 1488 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Celli A 62-Year-Old Woman With Chronic Obstructive Pulmonary Disease JAMA, November 26, 2003; 290(20): 2721 - 2729. [Full Text] [PDF]
|
|
|
|
|
|
P S Burge and S A Lewis So inhaled steroids slow the rate of decline of FEV1 in patients with COPD after all? Thorax, November 1, 2003; 58(11): 911 - 913. [Full Text] [PDF]
|
|
|
|
|
|
The pharmacoepidemiology of COPD: Recent advances and methodological discussion Eur. Respir. J., September 1, 2003; 22(43_suppl): 1s - 44s. [Full Text] [PDF]
|
|
|
|
|
|
D. D. Sin, S. F. P. Man, J. V. Tu, N. B. Pride, J. Vestbo, J. B. Soriano, and V. A. Kiri Inhaled glucocorticoids in COPD: Immortal time bias Am. J. Respir. Crit. Care Med., July 1, 2003; 168(1): 126 - 127. [Full Text] [PDF]
|
|
|
|
|
|
G. T. Ferguson, C. Funck-Brentano, T. Fischer, P. Darken, and C. Reisner Cardiovascular Safety of Salmeterol in COPD Chest, June 1, 2003; 123(6): 1817 - 1824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Burge and J.A. Wedzicha COPD exacerbations: definitions and classifications Eur. Respir. J., June 1, 2003; 21(41_suppl): 46S - 53s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M R Partridge Patients with COPD: do we fail them from beginning to end? Thorax, May 1, 2003; 58(5): 373 - 375. [Full Text]
|
|
|
|
|
|
E. Marchand Survival in COPD patients after regular use of fluticasone propionate and salmeterol Eur. Respir. J., March 1, 2003; 21(3): 559 - 560. [Full Text] [PDF]
|
|
|
|
|
|
J.B. Soriano, J. Vestbo, and N.B. Pride From the Authors Eur. Respir. J., March 1, 2003; 21(3): 560 - 560. [Full Text] [PDF]
|
|
|
|
|
|
J. Bourbeau Inhaled corticosteroids and survival in chronic obstructive pulmonary disease Eur. Respir. J., February 1, 2003; 21(2): 202 - 203. [Full Text] [PDF]
|
|
|
|
|
|
P.M.A. Calverley Medical therapy for COPD: lessons from the real world Eur. Respir. J., October 1, 2002; 20(4): 797 - 798. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |